Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
Patients with histologically confirmed esophagogastric junction adenocarcinoma with
pre-operative staging cT3-4N+M0，aged between 18-75 years old, with adequate organ function
and having an Eastern Cooperative Oncology Group performance status score ≤2, are randomized
in a 1:1:1 ratio to receive neoadjuvant chemoradiotherapy with DT46-50Gy plus concomitant
weekly oxaliplatin and 5-Fu, perioperative chemotherapy of FLOT regimen or FOLFOX regimen.
The primary end point is disease free survival (DFS), and secondary end point is 5-year
overall survival (OS), pathological complete remission (pCR) and treatment safety. The final
study analytics are to be conducted at the end of the 5th year after the last patient's
enrollment.